In summary, these data reveal that blocking the transcriptional activities of both full-length AR and truncated AR-Vs with ralaniten inhibits the expression of DDR genes, cell proliferation, as well as cell survival, thereby leading to increased sensitivity of prostate cancer to radiotherapy. The gene discussed is AR; the disease is prostate carcinoma.